DFTX

Market-moving news on Definium Therapeutics (NASDAQ: DFTX): filings, earnings, deals and other events, from REDFILED.

Definium is developing an orally disintegrating lysergide tablet for generalized anxiety disorder.

DFTX

DEFINIUM Posts Positive Phase 3 Panorama Data for LSD-Based Anxiety Drug

DT120 ODT cut Hamilton Anxiety scores 5.1 points more than placebo at Week 12, clearing the way for a pre-NDA meeting in 4Q 2026.

Rob Barrow, chief executive of Definium Therapeutics.

DFTX

FDA Grants DEFINIUM Second Breakthrough Therapy Tag for LSD Tablet

Definium's DT120 gets Breakthrough Therapy designation in major depressive disorder after a Phase 3 win, adding to an earlier tag in generalized anxiety.